A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa

Clinical trial NCT01154166 · COMPLETED

Trial details

NCT number: NCT01154166
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Parkinson Disease

Start date: 2010-02-15
Primary completion: 2011-09-01
Enrollment: 347

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.